Cannabinoids for the Treatment of Dermatologic Conditions
ReviewHumans
- Design
- Review
- Subjects
- 26 human studies (13 on systemic and 14 on topical cannabinoids) from 248 screened
- Dose used in the study
- Not stated in the abstract
- Duration
- Literature from 1965 to October 2020
- What was measured
- Which cannabinoids help dermatologic conditions, based on published human studies
What the authors reported
Of 248 nonduplicated studies screened, 26 were included (13 on systemic cannabinoids, 14 on topical). Selective CB2 agonists were reported effective in diffuse cutaneous systemic sclerosis and dermatomyositis; dronabinol for trichotillomania; sublingual CBD and THC for pain in epidermolysis bullosa. Cannabinoids may be effective for inflammatory skin disorders, the authors say, though more research is needed on dosing, safety and long-term use.
Limits of this study
A literature review; the abstract does not name palmitoylethanolamide or give PEA-specific results. Animal studies were excluded. Funding and conflicts not stated in the abstract.
Source
PubMed 35199092 · doi:10.1016/j.xjidi.2022.100095
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.